The evidence is in that asthma is not associated with severe coronavirus disease 2019
| Autor: | Mitchell H. Grayson, Dylan T Timberlake |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pulmonary and Respiratory Medicine
2019-20 coronavirus outbreak Poor outcomes Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Immunology CVD cardiovascular disease SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 Article medicine Prevalence Immunology and Allergy Humans Mortality RCT randomized controlled trial Respiratory disease Asthma COVID-19 coronavirus disease 2019 business.industry SARS-CoV-2 ES effect size COVID-19 MV mechanical ventilation medicine.disease Virology ICU intensive care unit CI confidence interval Meta-analysis PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analysis COPD chronic obstructive pulmonary disease AHRQ Agency for Healthcare Research and Quality business |
| Zdroj: | Annals of Allergy, Asthma & Immunology |
| ISSN: | 1534-4436 |
| Popis: | Background It is unclear if there is the influence of asthma on contracting COVID-19, or having worse outcomes from COVID-19 disease. Objective To explore the prevalence of asthma in COVID-19 patients and the relationship between asthma and COVID-19 patients with poor outcomes. Methods The pooled prevalence of asthma in COVID-19 patients and corresponding 95% confidence interval (CI) were estimated. The pooled effect size (ES) was used to evaluate the association between asthma and COVID-19 patients with poor outcomes. Results The pooled prevalence of asthma in COVID-19 patients worldwide was 8.3% (95% CI 7.6-9.0%) based on 116 articles (119 studies) with 403,392 cases. The pooled ES based on unadjusted effect estimates showed that asthma was not associated with the reduced risk of poor outcomes in COVID-19 patients (ES 0.91, 95% CI 0.78-1.06). Similarly, the pooled ES based on unadjusted effect estimates revealed that asthma was not associated with the reduced risk of mortality in COVID19 patients (ES 0.88, 95% CI 0.73-1.05). However, the pooled ES based on adjusted effect estimates indicated that asthma was significantly associated with the reduced risk of mortality in COVID-19 patients (ES 0.80, 95% CI 0.74-0.86). Conclusion The pooled prevalence of asthma in COVID-19 patients was similar to that in the general population, and asthma might be an independent protective factor for the death of COVID-19 patients, which suggests that we should pay high attention to COVID-19 patients with asthma and take locally tailored interventions and treatment. Further well-designed studies with large sample sizes are required to verify our findings. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|